Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Modified of cisplatin dose because of toxicities would compromise survival in head and neck cancer patients receiving chemoradiation therapy.
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: KUO, Jen-Hua (E-DA HOSPITAL, Kaohsiung City, China Taiwan)
- Co-author(s): Jen-Hua Kuo: Pharmacy, E-DA Hospital, Kaohsiung City, Taiwan, Province of China;Pharmacy, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
Yu-Chen Pan: Pharmacy, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
Yi-Ping Hsiang: Pharmacy, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
Yu-Chiun Sun: Department of Hematology/Oncology, E-DA HOSPITAL, Kaohsiung City, Taiwan, Province of China
BackgroundStandard cisplatin-based concurrent chemoradiotherapy (CCRT) has significantly improved locoregional control and survival in advanced squamous cell carcinoma of head and neck (SCCHN). However, this regimen has the disadvantages of intolerance and poor Compliance.
PurposeTo evaluate the impact of cisplatin dose reduction on prognosis of.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019